|
GB202103706D0
|
|
CD160 binding domain
|
|
GB202103114D0
|
|
High optical transmission amphiphobic surfaces; and methods of forming them
|
|
GB202102913D0
|
|
Methods and apparatus for transmitting and receiving data
|
|
GB202101958D0
|
|
Gene therapy for dopamine transporter deficiency syndrome
|
|
GB202100449D0
|
|
Subject positioning
|
|
GB202020549D0
|
|
Treatment for Lysine Degradation-associated Disorders
|
|
GB202020301D0
|
|
A system for positioning a medical tool
|
|
GB202020135D0
|
|
Immunogenic peptide
|
|
GB202019920D0
|
|
Automated microscopy
|
|
GB202019879D0
|
|
Polypeptide
|
|
GB202019418D0
|
|
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
GB202019084D0
|
|
Retroviral vectors
|
|
GB202018556D0
|
|
Oxide anode materials
|
|
GB202018068D0
|
|
Pharmaceutical composition
|
|
GB202017985D0
|
|
Methods for assessing vaginal microbiota community type
|
|
WO2021079122A1
|
|
Engineered regulatory t cell
|
|
GB202016624D0
|
|
Enhanced feedstock for additive manufacturing
|
|
GB202016058D0
|
|
Therapeautic treatment
|
|
WO2021053222A1
|
|
Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy
|
|
GB202014589D0
|
|
Agents for use in the treatment of amyloidosis
|
